News BriaCell Therapeutics Corp.

Stocks

BCT

CA1079303071

Biotechnology & Medical Research

Market Closed - Toronto S.E. 15:59:10 2026-09-01 EDT			5-day change	1st Jan Change
5.050 ^CAD	+1.61%		-1.75%	-48.47%

09:10pm	Certain Common Shares of BriaCell Therapeutics Corp. are subject to a Lock-Up Agreement Ending on 2-SEP-2026.	CI
09:10pm	Certain Warrants of BriaCell Therapeutics Corp. are subject to a Lock-Up Agreement Ending on 2-SEP-2026.	CI

All News

Mentions Relevance

09:10pm	Certain Common Shares of BriaCell Therapeutics Corp. are subject to a Lock-Up Agreement Ending on 2-SEP-2026.	CI
09:10pm	Certain Warrants of BriaCell Therapeutics Corp. are subject to a Lock-Up Agreement Ending on 2-SEP-2026.	CI
09:10pm	Certain Options of BriaCell Therapeutics Corp. are subject to a Lock-Up Agreement Ending on 2-SEP-2026.	CI
09:10pm	Certain Restricted Share Units of BriaCell Therapeutics Corp. are subject to a Lock-Up Agreement Ending on 2-SEP-2026.	CI
09:09pm	Certain Performance Share Units of BriaCell Therapeutics Corp. are subject to a Lock-Up Agreement Ending on 2-SEP-2026.	CI
08-24	BriaCell Therapeutics Corp. Advances Personalized Melanoma Immunotherapy Vaccine Candidate Bria-MEL+	CI
08-24	BriaCell Therapeutics : Advances Personalized Melanoma Immunotherapy Vaccine Candidate, Bria-MEL+(TM)	PU
08-24	BriaCell Advances Personalized Melanoma Immunotherapy Vaccine Candidate, Bria-MEL+™	AQ
08-05	BriaCell Gets FDA Approval to Start Phase 1/2a of Prostate Cancer Immunotherapy Study	MT
08-05	Briacell Therapeutics Corp Receives Fda Clearance to Initiate Bria-Pros+ Clinical Study in Prostate Cancer	CI
08-05	BriaCell Receives FDA Clearance to Initiate Bria-PROS+™ Clinical Study in Prostate Cancer	AQ
07-16	BriaCell Opens First Canadian Site For Phase 3 Metastatic Breast Cancer Study	MT
07-16	BriaCell Arranges Scalable Manufacturing with FUJIFILM Biotechnologies for Bria-IMT	AQ
07-16	BriaCell Therapeutics Corp. Opens First Canadian Site For Pivotal Phase 3 Trial In Metastatic Breast Cancer	CI
07-16	BriaCell Therapeutics : Opens First Canadian Site - Sunnybrook - for Pivotal Phase 3 Trial in Metastatic Breast Cancer	PU
07-16	BriaCell Opens First Canadian Site – Sunnybrook – for Pivotal Phase 3 Trial in Metastatic Breast Cancer	AQ
07-15	BriaCell Therapeutics : Arranges Scalable Manufacturing with FUJIFILM Biotechnologies for Bria-IMT(TM)	PU
07-15	BriaCell Arranges Scalable Manufacturing with FUJIFILM Biotechnologies for Bria-IMT™	AQ
07-07	BriaCell Engages Consulting and Branding Firms to Support Potential Commercialization of Bria-IMT	MT
07-07	BriaCell Engages Consulting and Branding Firms to Support Commercial and Market Access Evaluation of Bria-IMT™	AQ
06-25	BriaCell Partners with Uneedle for Scalable Microneedle Administration of Bria-IMT	CI
06-25	BriaCell Therapeutics Inks MOU With Dutch Microneedle Company	MT
06-25	BriaCell Therapeutics : Partners with Uneedle for Scalable Microneedle Administration of Bria-IMT(TM)	PU
06-25	BriaCell Partners with Uneedle for Scalable Microneedle Administration of Bria-IMT™	AQ
06-09	BriaCell Therapeutics Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended April 30, 2026	CI